Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVID™ Conditional Marketing Authorization to Full Marketing Authorization in the European Union
Pfizer
JANUARY 27, 2023
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. The European Commission (EC) will review the CHMP recommendation and is soon expected to make a final decision. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.
Let's personalize your content